These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 24275553)
1. HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system. Reyskens KM; Essop MF Biochim Biophys Acta; 2014 Feb; 1842(2):256-68. PubMed ID: 24275553 [TBL] [Abstract][Full Text] [Related]
4. Toward understanding induction of oxidative stress and apoptosis by proteasome inhibitors. Paniagua Soriano G; De Bruin G; Overkleeft HS; Florea BI Antioxid Redox Signal; 2014 Dec; 21(17):2419-43. PubMed ID: 24437477 [TBL] [Abstract][Full Text] [Related]
5. Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages. Zhang X; Cao R; Liu R; Zhao R; Huang Y; Gurley EC; Hylemon PB; Pandak WM; Wang G; Zhang L; Li X; Zhou H PLoS One; 2014; 9(3):e90856. PubMed ID: 24625618 [TBL] [Abstract][Full Text] [Related]
6. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections]. Pozio E Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694 [TBL] [Abstract][Full Text] [Related]
7. Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation. Touzet O; Philips A AIDS; 2010 Jun; 24(10):1437-47. PubMed ID: 20539089 [TBL] [Abstract][Full Text] [Related]
9. Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Rhew DC; Bernal M; Aguilar D; Iloeje U; Goetz MB Clin Infect Dis; 2003 Oct; 37(7):959-72. PubMed ID: 13130409 [TBL] [Abstract][Full Text] [Related]
11. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective. Bucher HC; Young J; Battegay M J Antimicrob Chemother; 2004 Aug; 54(2):303-5. PubMed ID: 15269200 [TBL] [Abstract][Full Text] [Related]
12. Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult spectrum of disease cohort. Vaughn G; Detels R AIDS Care; 2007 Apr; 19(4):492-9. PubMed ID: 17453589 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular considerations in patients treated with HIV protease inhibitors. Colagreco JP J Assoc Nurses AIDS Care; 2004; 15(1):30-41. PubMed ID: 14983559 [TBL] [Abstract][Full Text] [Related]
14. The ubiquitin-proteasome system and cardiovascular disease. Powell SR; Herrmann J; Lerman A; Patterson C; Wang X Prog Mol Biol Transl Sci; 2012; 109():295-346. PubMed ID: 22727426 [TBL] [Abstract][Full Text] [Related]
15. Metabolic Syndrome, Redox State, and the Proteasomal System. Höhn A; König J; Jung T Antioxid Redox Signal; 2016 Dec; 25(16):902-917. PubMed ID: 27412984 [TBL] [Abstract][Full Text] [Related]
17. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Piccinini M; Rinaudo MT; Anselmino A; Buccinnà B; Ramondetti C; Dematteis A; Ricotti E; Palmisano L; Mostert M; Tovo PA Antivir Ther; 2005; 10(2):215-23. PubMed ID: 15865215 [TBL] [Abstract][Full Text] [Related]
18. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. Calza L; Manfredi R; Chiodo F J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323 [TBL] [Abstract][Full Text] [Related]
19. Intersection of the Ubiquitin-Proteasome System with Oxidative Stress in Cardiovascular Disease. Qiu M; Chen J; Li X; Zhuang J Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293053 [TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of human mitochondrial diseases is modulated by reduced activity of the ubiquitin/proteasome system. Segref A; Kevei É; Pokrzywa W; Schmeisser K; Mansfeld J; Livnat-Levanon N; Ensenauer R; Glickman MH; Ristow M; Hoppe T Cell Metab; 2014 Apr; 19(4):642-52. PubMed ID: 24703696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]